Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (261)	2/6/1998 6:17:00 PM
From: Sam Quentin	Respond to of 1494

John, << NTII's patent position is strong and clear. Please tell me what I'm missing here?>> This may be what you're missing. If another company makes it to the market first then no matter how they are authorized to dispense the drug, we all know there's secondary prescribing done. Trying to figure this out -- stunned The best to all of us Sam

To: Dr. John M. de Castro who wrote (261)	2/7/1998 5:34:00 PM
From: John Wright	Respond to of 1494

>>>Please tell me what I'm missing here?<<<< John, I'd like to think nothing is missing however since the recent flury of announcements the share price is close to hitting its all time low. The so called 'market' seems to have either completely discounted all of the potential benefits you mention above or is simply so grossly ineffficient in the company's valuation. Being a finance guy, the efficient market pricing theory says a companys share price should reflect all publicly known and available information into the companys share price at any given time. So that the current valuation is fairly accurate. Is this the NTII case? I like to hope not. However, their is only so much cash left before it all becomes mute. Bye for now, John

To: Dr. John M. de Castro who wrote (261)	2/8/1998 6:59:00 PM
From: James Silverman	Respond to of 1494

John, A more pressing question for me is why no interest in memantine from big pharma or biotechs with related product lines (GILD/AGPH for example)? It has to say something that CNSI was able to license memantine for opthamalic uses to Allergan while NTII has been unable to license memantine for the seemingly far larger market opportunities. As memantine is an approved drug in Europe, for what indications is it approved for? What are its annual sales? How much off-label usage? Jim

To: Dr. John M. de Castro who wrote (261)	2/13/1998 2:43:00 AM
From: NW_Trader	Read Replies (1) \| Respond to of 1494

To Dr. John and All: The Evening News - or is it news? Comments? Thoughts? Prayers? Where does NTII go from here? biz.yahoo.com (extract follows without safe harbor stments and comparison tables) Neurobiological Technologies, Inc. Announces Second Quarter Results RICHMOND, Calif., Feb. 12 /PRNewswire/ -- Neurobiological Technologies, Inc. (OTC: NTII - news) announced a net loss of $1,200,000 or $0.18 per share -- basic and diluted, for its second quarter ended December 31, 1997. This compares to a net loss of $1,801,000 or $0.28 per share -- basic and diluted, for the same quarter a year ago. Research and development expenses decreased significantly to $448,000 in the three months ended December 31, 1997 from $1,318,000 in the same period of the prior year. The decrease was primarily due to the company narrowing its clinical focus to only the Phase II clinical development of Memantine and Xerecept(TM). General and administrative expenses increased to approximately $776,000 in the three months ended December 31, 1997 from $596,000 in the three months ended December 31, 1996. The increase was primarily due to professional services expenditures related to seeking financing and corporate partnerships in the three months ended December 31, 1997 as compared to the same period of the prior year. Interest income decreased to $24,000 in the three months ended December 31, 1997 from $113,000 in the same period of the prior year due to lower average cash balances. At December 31, 1997, the company had cash and cash equivalents of $1.4 million, and no long-term debt. The company anticipates that it will be able to meet its capital and operational requirements only until March 1998. The company will need to secure an infusion of capital to continue the clinical development of its product candidates. However there can be no assurance that funding will be available on favorable, if at all. Paul Freiman, president and chief executive officer of NTI said, ''I believe that the recently reported data from the company's controlled Phase II human clinical trial of Memantine will contribute significantly to our efforts to secure capital and obtain corporate partnerships. In our view, the trial results indicate Memantine's effectiveness in relieving neuropathic pain due to diabetes, a major unmet medical need. Many of the 800,000 diabetics in the U.S. treated annually for symptoms of peripheral neuropathy do not obtain adequate pain control from existing treatments.''

To: Dr. John M. de Castro who wrote (261)	2/19/1998 9:32:00 PM
From: diablo	Respond to of 1494

any further info on status of this company?

To: Dr. John M. de Castro who wrote (261)	2/20/1998 11:57:00 AM
From: Biomaven	Read Replies (1) \| Respond to of 1494

John, Here's a copy of a post I made yesterday on the VD thread. Any comments? ---------- I've been taking a look at NTII, currently exiled to the BB. Consider the following table in the report they just released: ntii.com Diabetic Patient Self-Assessment of Nocturnal Pain Measured on Visual Analogue Scale (VAS) of 1-100 8th Week of Treatment Memantine Placebo Number of Patients 28 37 Mean Nocturnal Pain Rating 31.2 44.4 Median Nocturnal Pain Rating 23.6 47.3 P-Value = .073 --------- So what we have here is that the median dropped much more than the mean. That indicates to me that there is probably a large subgroup for which it worked very well and another subgroup for which it did nothing much. Am I reading too much into the tea-leaves of a very empty cup? The stock looks tempting at these levels, except for the wicked spread and that little comment about running out of money in March... The stock price has been unchanged for about a week now, except for the bid/ask ping-pong. My gut tells me that they'll come up with something to keep them going, that Memantine will be partnered and the stock is a buy. My head tells me to put itself under a pillow until the feeling goes away ... Peter